The strategic alliance pairs Merck's wet lab biological data with the computational Drug Design Engine developed by DeepMind spinout Isomorphic Labs. Under the deal terms, Isomorphic secures an undisclosed upfront fee, milestone eligibility, and potential tiered product royalties, with an option to co-fund development for larger royalty cuts. Merck will manage all subsequent preclinical research, clinical trials, and manufacturing efforts. Notably, this arrangement comes immediately after Isomorphic secured billions in private capital and established drug discovery partnerships with several other major pharmaceutical companies.
Key points
The agreement grants Isomorphic an upfront payment alongside future milestone payments an…: The agreement grants Isomorphic an upfront payment alongside future milestone payments and tiered royalties tied to research, regulatory, and commercial metrics.
Isomorphic Labs retains an option to co-fund later development activities to secure incre…: Isomorphic Labs retains an option to co-fund later development activities to secure increased royalty rates on potential commercial drug sales.
Merck joins an expanding group of major pharmaceutical collaborators utilizing Isomorphic…: Merck joins an expanding group of major pharmaceutical collaborators utilizing Isomorphic's platform, including Novartis, Eli Lilly, and Johnson & Johnson.
Sources checked by our analysis pipeline: 1
Merck and Isomorphic Labs, the artificial intelligence drug designer built on a Nobel winning technology that can model how molecules will bind to proteins, said Thursday that they are entering into a research collaboration to discover small molecule candidates for an undisclosed oncology target of “strategic importance.”
The partnership — only the latest such deal between a pharma giant and Isomorphic — will bring together the latter’s proprietary drug design engine and existing wet lab data from Merck, officials from both companies said. Merck will handle the preclinical and clinical development, manufacturing, and commercializing of any products.
“It is a target of high interest to us, a target where we have deployed internal efforts, and we think the pairing of those datasets with the Isomorphic drug discovery engine technology could be a very powerful pairing,” said George Addona, global head of discovery, preclinical development, and translational medicine at Merck.
The aim is to use Isomorphic’s modeling and compute capabilities to expedite the discovery process. “At the end of the day, the ability for us to identify new ways to discover…
The maker of the Claude chatbot is heading to the public markets to test institutional appetite following a correction in tech equities driven by concerns over artificial intelligence spending. Early indications point to double-digit opening gains after the company secured over $107 billion through its offering and an accompanying private placement. This high-profile debut arrives at a pivotal moment as investors closely reassess the valuation of next-generation machine learning leaders.
Creators can now build augmented reality experiences by connecting third-party developer utilities directly into their existing production workflows. This cross-platform release broadens accessibility for creators across multiple desktop operating systems while modernizing the company's development pipeline. By embracing outside artificial intelligence environments, the software significantly expands technical options for digital lens design.
The initiative links automated software directly to more than 800 billing organisations, spanning public agencies, healthcare institutions, power companies, and telcos. By delegating routine obligations like fines and loan instalments to bots, the companies aim to remove friction while establishing technical guardrails to mitigate emerging financial risks.